Aging, Endothelial Dysfunction, Senescence
Conditions
Keywords
Endothelial Dysfunction, Senescence
Brief summary
In a healthy person, the production of nitric oxide (NO) by the endothelium, the inner lining of the blood vessel, is responsible for a) the ability of the blood vessel to dilate so it can increase its blood flow and b) act as an anti-clotting product to prevent blood clotting in those vessels. Under physiological stress either due to the development of a disease such as diabetes or simply from aging, the endothelial cells can be impacted and become dysfunctional, thereby impairing their ability to make NO and even promoting the development of blood clots. When such endothelial dysfunction occurs, it may be a precursor for the future development of cardiovascular (CV) disease like hypertension or coronary artery disease later on in life in these patients. Therefore, the ability to enhance the local production or availability of NO within such affected blood vessels in patients identified as prone to endothelial dysfunction could play a positive role in either preventing or delaying the onset of endothelial dysfunction and subsequent CV disease in such patients. RM is an oral supplement consisting of natural ingredients and the amino acid, L-citrulline. In laboratory experiments with cells from the inner lining of blood vessels, the four components of RM have been shown to increase the concentration of NO and decrease the levels of some aging markers. In our recently completed study (manuscript currently in review), 31 young men and women took the supplement for 14 days and had no serious side effects. The supplement caused the expected potentially beneficial dilation of the blood vessels and decrease in the levels of Plasminogen Activator Inhibitor-1 (PAI-1), whose levels correlate with aging and risk of cardiovascular disease. In this study, healthy participants will consume the supplement for a 6-week period to determine if PAI-1 levels continue to be suppressed and also examine whether the supplement has an effect on other blood markers whose levels can change with aging or cardiovascular disease and may also be indicative or predictive of an illness.
Detailed description
This study examines the effect of six weeks of daily supplementation on a panel of blood markers associated with vascular aging and inflammation. The blood markers Plasminogen Activator Inhibitor-1 (PAI-1), Interleukin-8 (IL-8), Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), Fibroblast Growth Factor 23 (FGF-23), C-Reactive Protein (CRP), and Klotho will be measured. PAI-1 is a protein involved in blood clotting whose elevated levels are associated with increased cardiovascular risk and aging. IL-8 is a pro-inflammatory cytokine linked to chronic inflammation. PCSK9 is involved in lipid metabolism and cardiovascular risk. FGF-23 is a regulator of phosphate metabolism and vascular calcification. CRP is a general marker of system inflammation, and Klotho is an anti-aging protein with protective effects on vascular and renal function. By assessing these markers, this study seeks to determine whether a natural oral supplement can modulate key pathways involved in vascular inflammation and aging, potentially positioning it as a natural oral supplement that may support vascular health in the context of age-related decline.
Interventions
Participants will consume a supplement called RM, which is composed of ginger extract, L-citrulline, and the herbal components Paullinia cupana and muira puama.
Sponsors
Study design
Intervention model description
35 healthy adult participants will be recruited. All participants will take the supplement twice daily for 6 weeks (42 days). Blood markers, blood pressure, and heart rate will be measured on day 0 and day 42.
Eligibility
Inclusion criteria
* People of any gender at least 18 years of age who do not have a history of acute or chronic cardiovascular illnesses are eligible.
Exclusion criteria
* Younger than 18 years of age * Currently pregnant (which will be confirmed by pregnancy test for participants capable of pregnancy) * Using hormonal birth control * Current smoker * Allergy to ginger, muira puama, Paullinia cupana, or L-citrulline * Previous use of Revactin® or RM * History of serious cardiovascular events, including myocardial infarction (heart attack) or stroke * History of coronary, cardiac, or carotid surgery such as a stent, heart surgery, or endarterectomy * Active cancer of any type other than skin cancer
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Blood Level of Plasminogen Activator Inhibitor-1 Between Baseline and 6 Months | From enrollment to the end of treatment at 6 weeks +/- 7 days | Blood levels of Plasminogen Activator Inhibitor-1 (PAI-1), a marker that correlates with aging and risk of cardiovascular disease, will be measured through a standard blood draw. Measurement units are ng/mL. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Blood Level of Interleukin-8 Between Baseline and 6 Months | From enrollment to the end of treatment at 6 weeks +/- 7 days | The blood marker Interleukin-8 (IL-8) will be measured through a standard blood draw. IL-8 is a pro-inflammatory cytokine linked to chronic inflammation. Measurement units are pg/mL. |
| Change in Blood Level of Proprotein Convertase Subtilisin/Kexin Type 9 Between Baseline and 6 Months | From enrollment to the end of treatment at 6 weeks +/- 7 days | The blood marker Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) will be measured through a standard blood draw. PCSK9 is involved in lipid metabolism and cardiovascular risk. Measurement units are ng/mL. |
| Change in Blood Level of Fibroblast Growth Factor 23 (FGF-23) Between Baseline and 6 Months | From enrollment to the end of treatment at 6 weeks +/- 7 days | The blood marker Fibroblast Growth Factor 23 (FGF-23) will be measured through a standard blood draw. FGF-23 is a regulator of phosphate metabolism and vascular calcification. Measurement units are pg/mL. |
| Change in Blood Level of C-Reactive Protein Between Baseline and 6 Months | From enrollment to the end of treatment at 6 weeks +/- 7 days | The blood marker C-Reactive Protein (CRP) will be measured through a standard blood draw. CRP is a general marker of systemic inflammation. Measurement units are mg/dL. |
| Change in Blood Level of Klotho Between Baseline and 6 Months | From enrollment to the end of treatment at 6 weeks +/- 7 days | The blood marker Klotho will be measured through a standard blood draw. Klotho is an anti-aging protein with protective effects on vascular and renal function. Measurement units are pg/mL. |
| Change in Blood Pressure Between Baseline and 6 Months | From enrollment to the end of treatment at 6 weeks +/- 7 days | Systolic and diastolic blood pressure will be measured. Measurement units are mm Hg. |
Countries
United States
Contacts
University of California, Los Angeles